Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2023-03-23 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第十六次会议审议事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific board meeting agenda items, including changes in the use of raised funds and amendments to registered capital and company type. It references a board meeting and legal compliance but does not contain financial statements or detailed financial data. It is a formal announcement related to board/management decisions rather than a full report or financial disclosure. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board opinions, not a full report or announcement of a report publication.
2023-03-23 Chinese
第四届监事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 15th meeting of the 4th Supervisory Board of Beijing Kangle Weishi Biotechnology Co., Ltd. It details meeting attendance, agenda items, voting results, and references to related announcements on the Beijing Stock Exchange information disclosure platform. The content focuses on corporate governance matters such as changes in investment project implementation and amendments to the company charter. It is not a full financial report, audit, or earnings release, nor is it a call transcript or dividend notice. It is a formal announcement of board-level decisions and governance actions, fitting the category of Board/Management Information (MANG). The document length is short and it does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. Therefore, the classification is MANG with high confidence.
2023-03-23 Chinese
中信证券股份有限公司关于北京康乐卫士生物技术股份有限公司变更募集资金投资项目实施主体和实施方式暨使用募集资金向全资子公司增资的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding changes in the implementation subject and method of the use of raised funds by Beijing Kanglevest Biotech Co., Ltd. It discusses the company's fundraising, the use of proceeds, changes in investment projects, and approvals by the board, supervisory committee, and independent directors. The document is not a full financial report but a regulatory compliance and verification statement related to capital raising and fund usage. It does not contain financial statements or earnings data but focuses on capital/financing updates and regulatory compliance regarding the use of raised funds. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5445 characters) and content confirm it is not merely an announcement but a substantive update on financing matters.
2023-03-23 Chinese
关于拟变更注册资本、公司类型及修订《公司章程》公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding proposed changes to the company's registered capital, company type, and amendments to the Articles of Association. It includes details about the capital increase, company structure changes, and references to relevant laws and regulatory approvals. The document is relatively short (1420 characters) and serves as a formal announcement of these corporate changes rather than a full report or detailed financial statement. It does not contain financial statements or detailed analysis but rather informs about corporate governance changes and capital structure updates. This fits best under the category of Share Issue/Capital Change (SHA), as it relates to changes in registered capital and company type.
2023-03-23 Chinese
关于签署募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for raised funds related to a public stock issuance. It details the amount raised, the use of funds, and the establishment of dedicated accounts for the funds. It references regulatory approval from the China Securities Regulatory Commission and includes specifics about the fundraising and fund management. The document is short (1156 characters) and focuses on the fundraising and capital management process rather than presenting financial statements or detailed financial results. Therefore, it fits the category of Capital/Financing Update (CAP).
2023-03-21 Chinese
北京康乐卫士生物技术股份有限公司超额配售选择权实施公告
Capital/Financing Update Classification · 95% confidence The document is titled as an "超额配售选择权实施公告" which translates to "Over-allotment Option Implementation Announcement." It details the exercise and implementation of an over-allotment option related to a public stock issuance and listing on the Beijing Stock Exchange. The content includes specifics about share allotment, share repurchase via market transactions, and related agreements. There is no financial statement or comprehensive financial report data present. The document is an announcement about the implementation of a capital market transaction (over-allotment option) related to share issuance and repurchase. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 3411 characters, which is relatively short but contains substantive information about financing activity, not just a notice of report publication. Therefore, the correct classification is CAP with high confidence.
2023-03-16 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.